Peer-influenced content. Sources you trust. No registration required. This is HCN.
MedPage Today
Anakinra (Kineret, Sobi) currently approved for rheumatoid arthritis and some rare disorders, was granted an emergency use authorization for a subgroup of COVID-hospitalized patients who are at risk of severe respiratory failure.
Family Medicine/General Practice November 29th 2022
MDLinx
MDLinx compiled a reading list of captivating books that have nothing to do with medicine—but might just help physicians realize some things about their work — and life.
Allergy & Immunology November 29th 2022
In the US, reports of COVID-related clots have declined. But social media posts in the UK indicate a rise there – and typically what the UK reports is a harbinger of what is coming to the US.
Allergy & Immunology November 9th 2022
The New England Journal of Medicine
In a randomized study involving 750 ICU patient on mechanical ventilation, minimizing sedation and employing daily physiotherapy did not yield better outcomes vs. standard care – but did increase the number of adverse events.
Emergency Medicine November 9th 2022
JAMA Network
The median time to recovery in a group of 1,800 vaccinated and unvaccinated adults (median age: 48 years) was essentially the same whether the patients received ivermectin or placebo: 12 and 13 days, respectively. Death rate was slightly higher in the ivermectin group and rates of pneumonia and VTE were slightly higher in the placebo group.
Allergy & Immunology November 2nd 2022
This study of 2,500 adults receiving mechanical ventilation randomized 1/3 were assigned to an exigent saturation target pf 90%, 1/3 to a target of 94%, and 1/3 to a target of 98%. The median number of ventilator-free days was 20, 21, and 21 for the three target groups, respectively. In-hospital death by day 28 was 34.8%, 34.0%, and 33.2% for the three groups, respectively.
Cardiology November 2nd 2022